News and Comments

The FDA Approves Gilead's HCV Drugs Harvoni and Sovaldi for Adolescents

  Sunday, April 09, 2017

The FDA Approves Harvoni® and Sovaldi® in Pediatric  More...

Neurocrine BioSciences (NBIX): Time for Transformation and Achievements

  Monday, March 27, 2017

Positive Results of INGREZZA on Tarditive Dyskinesia Highlights Neurocrine Biosciences Sciences and Scientists     More...

OncoCyte's Liquid Biopsy Test Has Positive News

  Wednesday, March 15, 2017

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests has good news about its lung cancer liquid biopsy. Liquid biopsy is a term recently coined for a simple blood test that can replace current invasive and expensive biopsy procedures for the detection of cancers at their early stages. This simple blood test is expected to lessen the need for invasive diagnostic methods such as surgical biopsies and cystoscopic procedures.    More...

Lexicon Pharmaceuticals: Cultivating the Fruits From Years of Lucrative Research

  Monday, March 06, 2017

A few days ago, the FDA approved Lexicon Pharmaceutical’s (LXRX) drug Xermelo™ (telotristat ethyl) 250 mg for the treatment of metastatic neuro-endocrine syndrome (mNET) patients who suffer from carcinoid syndrome diarrhea. The drug will be launched and sold today, March 6, in select specialty pharmacies.  More...

Exelixis: Important Collaborative Agreements with Roche and Bristol-Myers Squibb

  Monday, February 27, 2017

Exelixis (EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study of a combination of Exelixis cabozantinib in combination with Roche’s anti-PD-L1 immuno-therapy drug atezolizumab. The study aims at evaluating the safety and tolerability  of the combination in patients with locally advanced or metastatic solid tumors. Enrollment is scheduled to begin mid-year 2017; Exelixis will sponsor the trial, and Roche will provide atezolizumab.  More...

Agenus: Why Canceling Prophage Trial Should Not be Concerning

  Wednesday, February 22, 2017

Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline. The new checkpoint inhibitors products and their checkpoint targets products are the talk of the cancer community and having them has attracted large companies, including Incyte.  More...

Seattle Genetics' Agreement with Immunomedics: The Benefit Vs. the Risk

  Tuesday, February 14, 2017

Immunomedics (IMMU) and Seattle Genetics (SGEN) announced an exclusive global licensing agreement enabling Seattle Genetics to develop, fund, manufacture, and commercialize Immunomedics' solid tumor drug candidate IMMU-132.  More...

Interpreting Portola Pharmaceuticals' News

  Thursday, February 09, 2017

The FDA’s Center for Drug Evaluation and Research (CDER) informed Pertola (PTLA that it does not plan to hold an Advisory Committee meeting for its Product betrixaban.  More...

Companies Targeted for Takeover Yet Can Thrive on their Own

  Thursday, February 02, 2017

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become the best treatment choices are those that would accommodate the new wave of extremely promising immunotherapy approaches.     More...

Welcoming Jounce Therapeutics (JNCE) as a Public Company

  Friday, January 27, 2017

Today, Jounce Therapeutics has begun trading on the NASDAQ under the ticker symbol (JNCE).  The Company, which focuses on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the pricing of its initial public offering of 6,365,000 shares of common stock at a public offering price of $16.00 per share for aggregate gross proceeds of $101,840,000. In addition, Jounce granted the underwriters a 30-day option to purchase up to 954,750 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on January 27, 2017 under the ticker symbol “JNCE.” More...

Recent Postings



galapagos (GLPG) Exelixis (EXEL) AERIE PHARMACEUTICALS IDERA (IDRA) BIOMARIN (BMRN) ARCA (ABIO) REGULUS (RGLS) Ocular Therapeutix (OCUL) SERES THERAPEUTICS (MCRB) TOKAI (TKAOI) Global Cell Therapeutics (GBT) Sanofi-Aventis (SAN) Auspex (ASPX) Benlysta (belimumab) Roche (ROCHE) Biogen Idec (BIIB) Regeneron (REGN) Elan (ELN) Multiple Myeloma Anadys (ANDS) Agenus (AGEN) Aimmune Therapeutics (AIMT) AstraZeneca (AZN) Vitae Pharmaceuticals (VTAE) Bellicum (BLCM) Ionis (IONS) NEKTAR (NKTR)) Akebia Therapeutics (AKAB) Abbott Laboratories (ABT) JOUNCE THERAPEUTICS (JNCE) Herceptin Pluristem (PSTI) Bristol-Myers Squibb (BMY) GlycoMimetics (GLYN) OncoCyte (OCX) Amgen (AMGN) JUNO (JUNO) Endometrial Cancer ARGOS (ARGS) Intrexon (XON) Genentech Editas (EDIT) Alder Biopharmaceuticals (ALDR) Jazz Pharmaceuticals (JAZZ) Vertex (VRTX) Theravance Bio Pharma (TBPH) ACADIA (ACAD) Spike Therapeutics (ONCE) Array Pharmaceuticals (ARRY) Galena (GALE) Dendreon (DNDN) ADVENTRIX (ANX) Inovio (INO) Micromet (MITI) VANDA (VNDA) Sequenom (SQNM) Anacor (ANAC) Adaptimmune (ADAP) NEUROCRINE (NBIX) HALOZYME (HALO) Revlimid (lenolidamide) Alnylam (ALNY) Mirati Therapeutics (MRTX) PORTOLA (PTLA) GUARDIAN HEALTH Ariad (ARIA) Theravance (THRX) Sanofi (SNA) CompuGen (CGEN) LEXICON (LXRX) Prosensa (RNA) Velcade (bortezomib) Ziofpharm (ZIOP) C4 Therapeutics CRISPR Therapeutics (CRSP) Trastuzumab-DM1 Sarepta (SRPT) Agenus (AGEN Intercept (ICPT) AGOS (ARGS) Zerenex Telaprevir INNOVIVA (INVA) GlaxoSmithKline (GSK) Seattle Genetics (SGEN) Prolor Biotech (PBTH) CEMPRA (CEMP) ZALTRAP™ Roche (RHHBY) Biocryst (BCRX) MODERNA OSI (OSIP) Intermune (ITMN) Human Genome Sciences (HGSI) RenenxBio (RGNX) Dynavax (DVAX) Illumina (ILMN) ImmunoGen (IMGN) Epizyme (EPZM) ABBVIE (ABBV) Idenix (IDIX) SYNTA (SNTA) SUNESIS PHARMACEUTICALS (SNSS) PTC Therapeutics (PTCT) Ridaforolimus Merck (MRK) Cytokinetics (CYTK) Xoma (XOMA) NOVOCURE (NVCR) Human Longevity (HLI) KERYX (KERX) Sanofi (SNY) KITE (KITE) Sangamo (SGMO) Onyx (ONXX) Gilead (GILD) Advaxis (ADXS) Tysabri NANTKWEST (NK) Valeant Pharmaceuticals International (VRX) Incyte (INCY) ISIS (ISIS) Rapamune